Synlogic, Inc. a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States. Its lead therapeutic programs include SYNB1020, an oral therapy, which is in Phase I clinical trial for the treatment of patients with liver disease and hepatic encephalopathy, and urea cycle disorders; and SYNB1618, an oral therapy that is in Phase I/IIa clinical trial to treat phenylketonuria. The company is also involved in developing discovery-stage product candidates for inborn errors of metabolism, including maple syrup urine disease, isovaleric acidemia, and organic acidemias. It has a collaboration agreement with AbbVie S.à.r.l. to develop synthetic biotic medicines for the treatment of inflammatory bowel diseases; Ginkgo Bioworks to discover new living medicines to treat neurological and liver disorders. Synlogic, Inc. is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone617-401-9975
Debt
Current Ratio15.23
Quick Ratio15.23
Price-To-Earnings
Sales & Book Value
Annual Sales$2.44 million
Price / Sales77.60
Price / Cash FlowN/A
Price / Book1.87
Profitability
Net Income$-40,370,000.00
Net Margins-1,912.74%
Return on Assets-34.71%
Miscellaneous
Employees63
OptionableNot Optionable
Synlogic (NASDAQ:SYBX) Frequently Asked Questions
What is Synlogic's stock symbol?
Synlogic trades on the NASDAQ under the ticker symbol "SYBX."
When did Synlogic's stock split? How did Synlogic's stock split work?
Synlogic's stock reverse split before market open on Monday, August 28th 2017. The 1-7 reverse split was announced on Friday, August 25th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, August 25th 2017. An investor that had 100 shares of Synlogic stock prior to the reverse split would have 14 shares after the split.
How were Synlogic's earnings last quarter?
Synlogic Inc (NASDAQ:SYBX) announced its earnings results on Tuesday, November, 13th. The biotechnology company reported ($0.43) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.64) by $0.21. The biotechnology company had revenue of $1.80 million for the quarter, compared to analysts' expectations of $0.20 million. Synlogic had a negative return on equity of 39.07% and a negative net margin of 1,912.74%. View Synlogic's Earnings History.
When is Synlogic's next earnings date?
What price target have analysts set for SYBX?
6 analysts have issued 1-year price objectives for Synlogic's stock. Their predictions range from $15.00 to $26.00. On average, they anticipate Synlogic's share price to reach $19.80 in the next year. This suggests a possible upside of 166.1% from the stock's current price. View Analyst Price Targets for Synlogic.
What is the consensus analysts' recommendation for Synlogic?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Synlogic in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Synlogic.
What are Wall Street analysts saying about Synlogic stock?
Here are some recent quotes from research analysts about Synlogic stock:
- 1. According to Zacks Investment Research, "Synlogic, Inc. engaged in the development of a novel class of living Synthetic Biotic(TM) medicines based on its proprietary drug discovery and development platform. The company's pipeline includes Synthetic Biotic medicines for the treatment of rare genetic diseases such as Urea Cycle Disorder and Phenylketonuria. In addition, the company is leveraging the broad potential of its platform to create Synthetic Biotic medicines for the treatment of other diseases, such as liver disease, inflammatory and immune disorders and cancer. It is collaborating with AbbVie to develop Synthetic Biotic-based treatments for inflammatory bowel disease. Synlogic Inc., formerly known as Mirna Therapeutics Inc., is based in Cambridge, Massachusetts. " (1/5/2019)
- 2. Chardan Capital analysts commented, "We initiate coverage on Buy rating (PT$20) on its differentiated genetically-engineered live biotherapeutic product (LBP) platform, which targets metabolic and immune-mediated diseases. Synlogic is developing Synthetic Biotics, based on the probiotic E. coli Nissle engineered with gene circuits to break down toxic byproducts of metabolic dysfunction, either genetic or induced, or to modulate immune responses. While Synthetic Biotics are not intended to address dysbiosis, the chassis was originally derived from the microbiome of a healthy individual, so we include 2 (see Figure 1 and our 21 October research)." (12/13/2018)
- 3. HC Wainwright analysts commented, "We calculate an enterprise value of $515M, comprised of $385M for SYNB1020 in UCD and hyperammonemia in cirrhotic liver disease and I/O portfolio. This yields a price objective of $20.00 per share, assuming 25.6M shares outstanding as of end-2Q19. Risks include, but are not limited to: (1) slower-than- anticipated lead optimization to generate viable candidates for clinical development; (2) negative results from proof-of-concept clinical trials; (3) slower-than-anticipated clinical testing; and (4) inability to achieve approval for clinical candidates." (11/13/2018)
Has Synlogic been receiving favorable news coverage?
News articles about SYBX stock have trended somewhat negative on Wednesday, according to InfoTrie. InfoTrie identifies positive and negative news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Synlogic earned a coverage optimism score of -1.2 on InfoTrie's scale. They also assigned news articles about the biotechnology company a news buzz of 5.0 out of 10, indicating that recent news coverage is somewhat likely to have an impact on the stock's share price in the near future.
Who are some of Synlogic's key competitors?
Some companies that are related to Synlogic include Principia Biopharma (PRNB), AC Immune (ACIU), G1 Therapeutics (GTHX), Revance Therapeutics (RVNC), Radius Health (RDUS), Intra-Cellular Therapies (ITCI), Urogen Pharma (URGN), Rocket Pharmaceuticals (RCKT), Dynavax Technologies (DVAX), CannTrust (CNTTF), Dicerna Pharmaceuticals (DRNA), Vectura Group (VEGPF), ANI Pharmaceuticals (ANIP), Aurinia Pharmaceuticals (AUPH) and Ra Pharmaceuticals (RARX).
Who are Synlogic's key executives?
Synlogic's management team includes the folowing people:
- Dr. Peter Barrett, Exec. Chairman (Age 66)
- Dr. Aoife M. Brennan MB, BCh, BAO, MMSc, Pres, CEO & Chief Medical Officer (Age 44)
- Mr. Andrew W. Gengos, COO & Head of Corp. Devel. (Age 55)
- Dr. José Carlos Gutierrez-Ramos, Advisor (Age 57)
- Prof. Timothy K. Lu, Co-Founder
How do I buy shares of Synlogic?
Shares of SYBX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Synlogic's stock price today?
One share of SYBX stock can currently be purchased for approximately $7.44.
How big of a company is Synlogic?
Synlogic has a market capitalization of $187.55 million and generates $2.44 million in revenue each year. The biotechnology company earns $-40,370,000.00 in net income (profit) each year or ($5.88) on an earnings per share basis. Synlogic employs 63 workers across the globe.
What is Synlogic's official website?
How can I contact Synlogic?
Synlogic's mailing address is 301 Binney St. Suite 402, Cambridge MA, 02142. The biotechnology company can be reached via phone at 617-401-9975 or via email at [email protected]
MarketBeat Community Rating for Synlogic (NASDAQ SYBX)
MarketBeat's community ratings are surveys of what our community members think about Synlogic and other stocks. Vote "Outperform" if you believe SYBX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SYBX will underperform the S&P 500 over the long term. You may vote once every thirty days.
